Purification of erythropoietin from human plasma samples using an immunoaffinity well plate.
A method is described to isolate human erythropoietin (hEPO) from plasma using an EPO-specific immunoaffinity micro well plate (IAP). The operating conditions of the method (binding, blocking and elution) were optimised to avoid isoform discrimination and cross-contamination with other glycoproteins. The overall hEPO recovery was ca. 56% and significant clean-up for plasmatic hEPO was achieved. Polyvinylpyrrolidone (PVP) was used as a blocking reagent and elution took place at pH 11.0. Under these conditions all isoforms from recombinant human EPOs (rhEPOs) and analogues were uniformly recovered guaranteeing lack of discrimination. The resulting procedure allowed isolating erythropoietin from plasma in conditions amenable to hEPO analysis by other techniques such as SDS-PAGE or IEF. Moreover, avoiding contamination with other glycosylated material allowed the identification in human plasma samples of the non-human N-glycolyl-neuraminic acid (Neu5Gc) using HPLC-FLD. Neu5Gc is present as 1-2% of the sialic acid content in rhEPO so this approach could be used to unequivocally detect abuse of rhEPOs or analogues as part of the doping control.
Mallorquí
J
J
Bioanalysis Group, Neuropsychopharmacology Research Program, IMIM-Hospital del Mar. PRBB, Barcelona, Spain.
Llop
E
E
de Bolòs
C
C
Gutiérrez-Gallego
R
R
Segura
J
J
Pascual
J A
JA
D002851:Chromatography, High Pressure Liquid; D004797:Enzyme-Linked Immunosorbent Assay / Q000295:instrumentation* / Q000379:methods*; D004921:Erythropoietin / Q000097:blood* / Q000302:isolation & purification*; D006801:Humans; D007525:Isoelectric Focusing; D012015:Reference Standards
D004921:Erythropoietin